PBA
GRCL

Paradigm Biocapital Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Paradigm Biocapital Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-783,445
Closed -$4.31M – 32
2022
Q2 		$4.31M Hold
783,445
– – 0.86% 21
2022
Q1 		$1.82M Buy
783,445
+238,057
+44% +$811K 0.48% 25
2021
Q4 		$3.29M Buy
+545,388
New +$5.24M 0.94% 24

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Paradigm Biocapital Advisors's GRCL Position: Q3 2022 in Review

Paradigm Biocapital Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q3 2022, closing a stake of 783,445 shares — an estimated $4.31M sold.

Paradigm Biocapital Advisors first reported a position in GRCL in Q4 2021 and held it in 3 quarters. The position peaked at $4.31M in Q2 2022. 33 funds tracked by Wall St. Rank hold GRCL as of Q3 2022.

  • Paradigm Biocapital Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 783,445 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2022, an estimated $4.31M.
  • Paradigm Biocapital Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2021 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $4.31M in Q2 2022.
  • 33 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.